Skip to Main Content

Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, however, is rather quiet this morning as the short person has bolted for a quick trip to the shore now that school is out, and the official mascots have settled in for their usual snooze. As for us, we are firing up the coffee kettle as we prepare to forage for items of interest. Speaking of which, here are a few tidbits to start you on your way. Hope all goes well and, as always, we hope you will stay in touch. We accept dossiers, encrypted messages, satellite signals, and postcards …

Earlier this month, BrainStorm Cell Therapeutics (BCLI) disclosed plans to offer an experimental treatment for ALS, or amyotrophic lateral sclerosis, under the recently enacted federal “right to try” law. At the time, chief executive officer Chaim Lebovits made it clear that he hopes to do so if legal, ethical, and business challenges can be resolved. “I think you can hear between the lines where our heart is,” he said. But there is a catch — the company may charge more than $300,000. “We have to have an incentive,” he tells Bloomberg News.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!